Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**AZD3480 + donepezil** is a combination of two drugs: AZD3480, a selective agonist of central neuronal nicotinic acetylcholine receptors (primarily α4β2 and α2β2), and donepezil, a reversible acetylcholinesterase inhibitor. AZD3480 acts to stimulate neuronal nicotinic cholinergic receptors, potentially enhancing cognitive function, while donepezil inhibits acetylcholinesterase, thereby increasing synaptic acetylcholine and improving cognitive and behavioral symptoms of Alzheimer's disease. The combination has primarily been investigated in early-stage research and pharmacokinetic studies aiming to assess potential cognitive benefits and drug-drug interactions in the context of Alzheimer's disease and related dementias[1][2][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on AZD3480 + donepezil.